GSK: Cervical cancer vaccine protects for more than five years

04/17/2007 | Forbes

GlaxoSmithKline released new data showing its cervical cancer vaccine Cervarix prevents pre-cancerous lesions caused by two viruses for five and a half years. GSK has applied to U.S. and European regulators for approval of the vaccine, which would compete with Merck's Gardasil.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC